Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Janux Therapeutics, Inc. (NASDAQ:JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE:BMY) .San Diego-based Janux will receive up to $50 million in upfront and near-term milestone payments, with potential total payments reaching approximately $800 million, including royalties on global product sales.The collaboration allows Janux to complete preclinical development up to Investigational New Drug (IND) submission, while Bristol Myers Squibb ...